Small Molecules
10 February 2016
Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study10 February 2016
vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes9 February 2016
Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD9 February 2016
Phase III trial with PM1183 in ovarian cancer (CORAIL) continues on the basis of positive recommendation by IDMC9 February 2016
Paion discontinues European remimazolam phase III trial in cardiac surgery patients due to insufficient recruitment8 February 2016
BioCryst Announces Results From OPuS-28 February 2016
Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 – Oral Encochleated Amphotericin B5 February 2016
EMA Reaffirms Positive Benefit-Risk Balance of Bayer’s Xarelto® for Stroke Prevention in Patients with Atrial Fibrillation4 February 2016
Ignyta Announces Initiation of Phase 1/1b Clinical Trial of Taladegib in Combination with Paclitaxel by Cancer Research UK3 February 2016
Lixte Biotechnology Holdings, Inc.’s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression3 February 2016
Psyadon Announces Positive Independent Review of Phase 2b Study of Ecopipam for the Treatment of Tourette’s Syndrome in Children2 February 2016
Ziarco Pharma Ltd – Phase 2a Psoriasis Study Initiated with Ziarco’s Lead Compound ZPL-389News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports